Swiss AI drug trial startup receives funding from Spotify-backer Creandum
An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.
- ✓An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.
- ✓KYC and KYB: Inside Damani’s Avenue Supermarts that refuses to charge more – Part 1 of 3Will oil turn into a lingering problem?
- ✓Civic Domain: Categorized under technology public notices.
(Catch all the Technology News News, and Latest News Updates on The Economic Times.) SynopsisAn AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.
AgenciesZURICH: Swiss AI start-up Atlast Bio, which runs drug trials on virtual patients, has received $12.5 million in funding led by Swedish venture capital firm Creandum, an early backer of Spotify and Trade Republic, the company said on Tuesday.
* Atlas Bio is aiming to replace Phase II drug trials, which it says cost more than $100 million, take two to three years and see about 70% of drugs fail at that stage * An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said * Virtual trials can also evaluate drugs across multiple diseases simultaneously, something not feasible in conventional clinical trials, Atlas Bio added * Atlas Bio was founded by former Google employees alongside AI and pharmaceutical specialists Read more news onAtlast BioCreandumAI drug trialsdrug developmentvirtual patientsfunding for biotechatlas bioAI foundation model (Catch all the Technology News News, and Latest News Updates on The Economic Times.) Elevate your knowledge and leadership skills at a cost cheaper than your daily tea.
KYC and KYB: Inside Damani’s Avenue Supermarts that refuses to charge more – Part 1 of 3Will oil turn into a lingering problem? Is the world economy, India, or the market prepared?KYB and KYC: Business behind the wealth creator called ‘Divi’s Lab’ – Part 2, concludingKYB and KYC: Business behind the wealth creator called “Divi’s Lab” – Part 1The global business of promising moreOne company, 2 words.
Bond yield and CDS: Will they decide the fate of global markets?Business of Odd Things: Inside an industry that farms fish that nobody is meant to eatWar's second-order effects are becoming visible in critical sectorsUS mid-term elections – Part 2: What does it mean for Trump to lose control of Congress?Homebuyers wait as NCLT panel picks holes in unfinished Jaypee projects
- •Aspirants and citizens are advised to monitor official notices and circulars issued by ET Tech & Digital India.
- •Verify all prescribed eligibility criteria, cutoff dates, and authenticated document requirements prior to formal submissions.
- •Track connected examination timetables, vacancy advisories, and administrative gazettes on SuchnaSetu.
| Issuing Authority | ET Tech & Digital India |
|---|---|
| Topic Category | TECHNOLOGY |
| Jurisdiction | All India / National |
| Publication Date | 27 October 2026 |